Stocks in play: PharmaTher Holdings Ltd.
Announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining the novel use of ketamine as a potential treatment for Type 2 diabetes and obesity, based on the evaluation of the Company’s drug repurposing artificial intelligence (“AI”) platform, panaceAI™. PharmaTher is also advancing research with panaceAI™ to evaluate repurposing opportunities with N,N-Dimethyltryptamine (“DMT”), 3,4-Methylenedioxy methamphetamine (“MDMA”) and lysergic acid diethylamide (“LSD”) for future clinical development and partnering opportunities. PharmaTher Holdings Ltd. shares C.PHRM are trading unchanged at $0.24.
Read:
The Digestive Health Market Could Help Fuel a Nearly $72 Billion Opportunity
Psychedelics Could Help Treat the 463 Million People Coping with Diabetes
Global Companies Quickly Learning Employee Mental Health is Worth the Investment
The Electric Vehicle Market is Facing a Severe Metal Shortage
Data Revenue Grows by 95% as EQ Works Continues to Build Upon its Data Offerings